A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 29 Dec 2017
Price : $35 *
At a glance
- Drugs Girentuximab I-124 (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- Acronyms REDECT 2
- Sponsors WILEX Inc
- 20 Dec 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 20 Dec 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
- 20 Dec 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.